CN110522669A - It is a kind of effectively to inhibit beauty polypeptide enzymatic biodegrading process - Google Patents
It is a kind of effectively to inhibit beauty polypeptide enzymatic biodegrading process Download PDFInfo
- Publication number
- CN110522669A CN110522669A CN201910766590.1A CN201910766590A CN110522669A CN 110522669 A CN110522669 A CN 110522669A CN 201910766590 A CN201910766590 A CN 201910766590A CN 110522669 A CN110522669 A CN 110522669A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- beauty
- enzymatic
- effectively
- tranexamic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 77
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 70
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 70
- 230000003796 beauty Effects 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 22
- 230000008569 process Effects 0.000 title claims abstract description 15
- 230000002255 enzymatic effect Effects 0.000 title claims abstract description 14
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims abstract description 25
- 229960000401 tranexamic acid Drugs 0.000 claims abstract description 24
- 239000002537 cosmetic Substances 0.000 claims abstract description 20
- 230000002087 whitening effect Effects 0.000 claims description 4
- 208000003351 Melanosis Diseases 0.000 claims description 2
- 230000003255 anti-acne Effects 0.000 claims description 2
- 230000003266 anti-allergic effect Effects 0.000 claims description 2
- 230000003020 moisturizing effect Effects 0.000 claims description 2
- PLISWQKGWPUZID-UHFFFAOYSA-N 2-hydroxy-4-methoxybenzoic acid;potassium Chemical compound [K].COC1=CC=C(C(O)=O)C(O)=C1 PLISWQKGWPUZID-UHFFFAOYSA-N 0.000 claims 1
- 108010016626 Dipeptides Proteins 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000007515 enzymatic degradation Effects 0.000 abstract description 20
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000003631 expected effect Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 102000004400 Aminopeptidases Human genes 0.000 description 5
- 108090000915 Aminopeptidases Proteins 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical group CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 description 1
- 101000761020 Dinoponera quadriceps Poneritoxin Proteins 0.000 description 1
- 235000002673 Dioscorea communis Nutrition 0.000 description 1
- 241000544230 Dioscorea communis Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000035753 Periorbital contusion Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses one kind effectively to inhibit beauty polypeptide enzymatic biodegrading process, addition tranexamic acid and 4MSK in containing beauty polypeptide solution, and the addition molar ratio of tranexamic acid and 4MSK are 1:1.The present invention is effectively reduced polypeptide and is degraded, retain polypeptide complete structure and bioactivity, have expected effect in cosmetic industry field to biologically active polypeptide by inhibiting biologically active polypeptide enzymatic degradation.
Description
Technical field
The invention belongs to cosmetic fields, in particular to a kind of effectively to inhibit biologically active polypeptide enzymatic degradation method, with
And the application with its medical applications, especially beautifying skin.
Background technique
Beauty polypeptide is the small molecular protein that a kind of amino acid with certain sequence is connected by amido bond, research hair
It is existing, it plays an important role in skin natural aging and nursing process, such as cell Proliferation, cell migration, inflammation, blood vessel
Occur, pigment is formed and albumen synthesis and regulation etc..
In cosmetic field, beauty polypeptide has become a kind of important active constituent, In in anti crease and anti senile old field
Eye haustra -dsipelling and black eye, whitening body beautification, promotion hair growth etc. have also played unmatched effect.Bioactivity is more
Peptide peptide is widely used in famous brand name, Estee Lauder, Lancome, refined of Elizabethan, SK-II, KOSE, Olay etc.
High Tier Brand skin care kind all has begun addition polypeptide into the anti-ageing product of its high price.
But that there are stability in human body is poor for beauty polypeptide, the various enzymes easily carried by human body digest cause it is more
The fracture of peptide peptide bond change polypeptide as a result, lose reactivity, to reduce the physiological function for even completely losing script.
The study on the modification to polypeptide self structure is all concentrated on for the existing method of inhibition polypeptide enzymatic degradation at present,
In vitro such as ferrocene-peptide molecule with blocking effect by being gradually condensed the method combined with fragment condensation synthesis
Promote degradation capability with stronger antienzyme；It is mentioned by polyethylene glycol (PEG) modification technique, the modification of polypeptide N-terminal, chemiluminescent polypeptide modification
The antienzyme for being improved in varying degrees polypeptide with polypeptide fatty acid modifying promotees degradation capability.Existing polypeptide antienzyme promotees degradation technique tool
There is the safety of polypeptide after changing for single polypeptide validity, adaptability narrow range, and structure to need to be investigated, in cosmetics function
Effect, which is used, certain limitation.Therefore, a kind of polypeptide antienzyme rush biodegrading process that can be quickly applied to cosmetics is developed, for
Application of the polypeptide in cosmetics has important research significance.
Summary of the invention
In view of the deficiencies of the prior art, the present invention provides a kind of effectively inhibition beauty polypeptide enzymatic biodegrading process, and
The medical usage of the compound, especially beautifying skin, including repair field application,
To achieve the above object, the present invention provides the following technical scheme that
It is a kind of effectively to inhibit beauty polypeptide enzymatic biodegrading process, comprising adding tranexamic acid in beauty polypeptide stoste.
It is a kind of effectively to inhibit beauty polypeptide enzymatic biodegrading process, comprising adding tranexamic acid and 4MSK in beauty polypeptide stoste.
It is a kind of effectively to inhibit beauty polypeptide enzymatic biodegrading process in cosmetic applications, in the product comprising beauty polypeptide,
The addition molar ratio of tranexamic acid and 4MSK are 1:1.
Preferably, the cosmetics are whitening, nti-freckle, crease-resistant, moisturizing, anti-acne, antiallergic, all kinds of cosmetics systems such as releive
Agent.
In summary:
Tranexamic acid is a kind of protease inhibitors, can effectively catalytic action of the protease inhibition to peptide bond hydrolysis, can effectively inhibit
Polypeptide by enzymatic degradation, improve the stability of polypeptide.4MSK and salicylic acid have similar structure, studies have shown that 4MSK with
Tranexamic acid compounds the permeability that can effectively improve tranexamic acid.In the present invention, in the stoste containing beauty polypeptide, tranexamic acid
The permeability of tranexamic acid can most preferably be improved with the addition for compounding 1:1 molar ratio of 4MSK, thus the suppression for making tranexamic acid more efficient
Degradation of the enzyme processed to polypeptide, can not only be effectively improved the enzymatic degradation of polypeptide, improve the cosmetic industry of polypeptide, can be with simultaneous
Have Whitening, spot, there is significant meaning to the exploitation of effect type cosmetics.
Detailed description of the invention
Fig. 1 is the polypeptide enzymatic degradation process figure of embodiment 1-6；
Fig. 2 is the polypeptide enzymatic degradation process figure of embodiment 7-10.
Specific embodiment
Effectively the embodiment of beauty polypeptide enzymatic biodegrading process is inhibited to be described further one kind of the invention:
Embodiment 1
(1) raw material for standby is weighed according to following proportion
A:GHK 0.01%, glycerol 20-30%, 1,2 hexylene glycol 1-5%, Sensiva SC50 0.05-0.5%, water 70-80%, configuration
Cosmetics stoste, configuration are completed to detect initial peptide content；
B: aminopeptidase 0.2-2g
C: tranexamic acid 1-3%
(2) stirring and dissolving in A is added in appropriate B to dispense, standing 30min, 90min, 120min is examined by HPLC after C stirring is added
Survey peptide content variation.
Embodiment 2
(1) raw material for standby is weighed according to following proportion
A:GHK 0.01%, glycerol 20-30%, 1,2 hexylene glycol 1-5%, Sensiva SC50 0.05-0.5%, water 70-80%, configuration
Cosmetics stoste, configuration are completed to detect initial peptide content；
B: aminopeptidase 0.2-2g
C: tranexamic acid mixes molar ratio 1:1, total amount of adding 1-3% with 4MSK.
(2) stirring and dissolving in A is added in appropriate B to dispense, standing 30min, 90min, 120min pass through after C stirring is added
HPLC detects peptide content variation.
Embodiment 3
3 difference from Example 2 of embodiment is: tranexamic acid mixes molar ratio 2:1 with 4MSK in C.
Embodiment 4
4 difference from Example 2 of embodiment is: tranexamic acid mixes molar ratio 3:1 with 4MSK in C.
Embodiment 5
5 difference from Example 2 of embodiment is: tranexamic acid mixes mole with 4MSK in C: 1:2.
Embodiment 6
6 difference from Example 2 of embodiment is: tranexamic acid mixes molar ratio 1:3 with 4MSK in C.
Embodiment 7
7 difference from Example 2 of embodiment is: GHK is GHK-CU in A.
Embodiment 8
8 difference from Example 1 of embodiment is: GHK is palmityl tripeptides -1 in A.
Embodiment 9
9 difference from Example 1 of embodiment is: GHK is class snake venom peptide in A.
Embodiment 10
10 difference from Example 1 of embodiment is: GHK is Matrixyl -4 in A.
Polypeptide enzymatic degradation process in embodiment 1-10 is analyzed respectively.Blank is that C test result is not added.
Fig. 1 result can be seen that inhibits polypeptide enzymatic biodegrading process that polypeptide enzymatic can effectively be inhibited to drop using the present invention
Solution preocess.The polypeptide of tranexamic acid and 4MSK are not added under the action of aminopeptidase, 30min peptide content reduces nearly 50%, 120min peptide
Content reduces nearly 90%, and it is complete that polypeptide promotees degradation by aminopeptidase substantially.It is compared after addition tranexamic acid, the polypeptide of 120min detection contains
Amount obviously increases, and the enzymatic degradation of polypeptide is effectively suppressed.It is found after adding 4MSK further according to different proportion, polypeptide
Better than individually addition tranexamic acid, tranexamic acid are compounded with 4MSK and are applied together with polypeptide enzymatic degradation process inhibitory effect, energy
Enough polypeptide enzymatic degradations that efficiently improves reach 80%.It finds in the course of the research simultaneously, inhibits the enzymatic degradation and tranexamic acid of polypeptide
There are certain relationships with the ratio of 4MSK, in the cosmetics containing beauty polypeptide, when tranexamic acid and 4MSK molar ratio are 1:1,
It is optimal the enzymatic degradation inhibiting rate of polypeptide.By the invention, it can effectively inhibit up to 80% or more polypeptide enzymatic
Degradation.
Fig. 2 is preferably to detect polypeptide not of the same race in the effect of aminopeptidase under conditions of tranexamic acid and 4MSK molar ratio 1:1
Under enzymatic degradation process, the results showed that, can effectively be inhibited using enzymatic degradation process of the present invention to multiple polypeptides.
Wherein enzymatic degradation inhibition of the GHK-CU in 120min is up to about 80%, and similar to GHK, other kind polypeptides have 40-50%
Inhibition enzymatic degradation.The method of the present invention is applicable in but is not limited to the enzymatic degradation inhibition of one or more polypeptides, has efficiently suitable
Ying Xing can significantly inhibit the enzymatic degradation of polypeptide, greatly improve polypeptide in the products application containing beauty polypeptide
Activity improves its beauty functions in cosmetics.
In summary:
The above content is combine specifically to repair to select embodiment further detailed description of the invention, and it cannot be said that this hair
Bright specific implementation is only limited to these instructions, and for those of ordinary skill in the art to which the present invention belongs, is not being taken off
Under the premise of from present inventive concept, a number of simple deductions or replacements can also be made, all shall be regarded as belonging to protection of the invention
Range.
Claims (5)
1. a kind of effectively inhibit beauty polypeptide enzymatic biodegrading process, it is characterised in that: including the cosmetics of (A) beauty polypeptide
Middle addition (B) tranexamic acid.
2. a kind of as described in claim 1 effectively inhibit beauty polypeptide enzymatic biodegrading process, which is characterized in that (A) beauty polypeptide
Refer to the one or more of dipeptides, tripeptides, tetrapeptide, pentapeptide.
3. a kind of as described in claim 1 effectively inhibit beauty polypeptide enzymatic biodegrading process, which is characterized in that including (A)
The cosmetics of beauty polypeptide further add (C) 4- methoxysalicylic acid potassium (4MSK).
4. a kind of as described in claim 1-3 effectively inhibit beauty polypeptide enzymatic biodegrading process, it is characterised in that: answered in cosmetics
In, in the product comprising beauty polypeptide, the addition molar ratio of component (B) and (C) are 1:1-3:1.
5. application according to claim 4, the cosmetics are whitening, nti-freckle, crease-resistant, moisturizing, anti-acne, antiallergic, releive
Etc. all kinds of cosmetic formulations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910766590.1A CN110522669A (en) | 2019-08-20 | 2019-08-20 | It is a kind of effectively to inhibit beauty polypeptide enzymatic biodegrading process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910766590.1A CN110522669A (en) | 2019-08-20 | 2019-08-20 | It is a kind of effectively to inhibit beauty polypeptide enzymatic biodegrading process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110522669A true CN110522669A (en) | 2019-12-03 |
Family
ID=68663626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910766590.1A Pending CN110522669A (en) | 2019-08-20 | 2019-08-20 | It is a kind of effectively to inhibit beauty polypeptide enzymatic biodegrading process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110522669A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113662882A (en) * | 2021-10-09 | 2021-11-19 | 上海新高姿化妆品有限公司 | Whitening, spot-fading and tightening essence and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105963153A (en) * | 2016-07-15 | 2016-09-28 | 广州瑞朗生物科技有限公司 | Active composition containing copper peptide and cosmetic or skin care product |
| CN109549863A (en) * | 2018-12-24 | 2019-04-02 | 深圳市琉璃光生物科技有限公司 | A kind of lightening compositions and preparation method thereof |
| CN109602687A (en) * | 2019-02-20 | 2019-04-12 | 王清秀 | A kind of whitening spot-eliminating composition |
| CN109846741A (en) * | 2018-08-31 | 2019-06-07 | 上海珈凯生物科技有限公司 | A method of methoxysalicylic acid potassium, which is improved, with tranexamic acid compounds stability |
-
2019
- 2019-08-20 CN CN201910766590.1A patent/CN110522669A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105963153A (en) * | 2016-07-15 | 2016-09-28 | 广州瑞朗生物科技有限公司 | Active composition containing copper peptide and cosmetic or skin care product |
| CN109846741A (en) * | 2018-08-31 | 2019-06-07 | 上海珈凯生物科技有限公司 | A method of methoxysalicylic acid potassium, which is improved, with tranexamic acid compounds stability |
| CN109549863A (en) * | 2018-12-24 | 2019-04-02 | 深圳市琉璃光生物科技有限公司 | A kind of lightening compositions and preparation method thereof |
| CN109602687A (en) * | 2019-02-20 | 2019-04-12 | 王清秀 | A kind of whitening spot-eliminating composition |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113662882A (en) * | 2021-10-09 | 2021-11-19 | 上海新高姿化妆品有限公司 | Whitening, spot-fading and tightening essence and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102317307B (en) | Peptides used in the treatment and/or care of the skin, mucous membranes and/or scalp and their use in cosmetic or pharmaceutical compositions | |
| JP6100364B2 (en) | Whitening accelerator or atopic dermatitis improving agent | |
| Forghani et al. | Purification and characterization of angiotensin converting enzyme-inhibitory peptides derived from Stichopus horrens: Stability study against the ACE and inhibition kinetics | |
| CN101675067B (en) | Modifications of peptide compositions to increase stability and delivery efficiency | |
| CN102015764B (en) | Cosmetic or pharmaceutical compositions comprising metalloproteinase inhibitors | |
| ES2397890B1 (en) | USEFUL PEPTIDES IN THE TREATMENT AND / OR CARE OF SKIN AND / OR MUCOSES AND ITS USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS. | |
| KR20150143752A (en) | Compounds useful in the treatment and/or care of the skin and their cosmetic or pharmaceutical compositions | |
| KR102077983B1 (en) | Composition for improving skin wrinkles and skin whitening | |
| CN101384274B (en) | Compositions containing peptides with non-natural amino acids and methods of use | |
| EA201100459A1 (en) | COMPOSITIONS INCLUDING INTERLEUKIN-1 AND PEPTIDES | |
| Tałałaj et al. | The effects of a novel series of KTTKS analogues on cytotoxicity and proteolytic activity | |
| CN110522669A (en) | It is a kind of effectively to inhibit beauty polypeptide enzymatic biodegrading process | |
| HUP0000320A2 (en) | Peptide and a method of obtaining it | |
| CN103747793A (en) | Composition containing soy protein hydrolyzate | |
| JP2019528289A (en) | Minoxidil and peptide conjugates | |
| CN102428095B (en) | Novel proteasome-activating anti-aging peptides and compositions containing same | |
| KR20140134282A (en) | Bifunctional peptide | |
| JP2020519622A (en) | Conjugate of isotretinoin and peptide | |
| JP2019526276A (en) | Novel AIMP1 protein fragment and skin protecting composition comprising the same as an active ingredient | |
| Morihara et al. | Effect of secondary interaction on the enzymatic activity of trypsin-like enzymes from Streptomyces | |
| KR20050092026A (en) | Method to increase fibronectin | |
| JP2007039394A (en) | External preparation for skin for preventing and ameliorating aging | |
| CN112040968B (en) | Bioactive peptides with high binding affinity to human muscle nicotinic acetylcholine receptors | |
| US20220193180A1 (en) | Aging progression suppressing agent, and food or beverage product comprising same | |
| Rodan et al. | Bioactive peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191203 |